England’s new £340m ($428m) Innovative Medicines Fund (IMF) offers new and earlier opportunities for companies to achieve market access where once they may have failed. However, companies should give careful consideration to both the potential advantages and risks of entering the fund, including the costs of gathering additional data, advised Caroline Hall, director of global market access & support at AmerisourceBergen’s Xcenda, a health care consultancy.
Launched in June, the fund will operate as a managed access fund along the lines of England’s interim funding mechanism,...